Comment · Mon, March 2, 2015
2-FMA harm reduction.
Original post in this thread
redan-yadayada · 17 points
Without encouraging any further use of this compound (and not knowing exactly where to post this), I'm wondering how does one counter the risk associated with possible agonist effects on the 5-HT2B receptor due to 2-FMA and its metabolites? Thanks.
What they were answering
FW900 · 6 points
Taking a peripheral 5-HT2B antagonist would theoretically counteract the adverse cardiovascular effects of 2-FMA.
Given that most people who use 2-FMA tend to use it as a study drug or productivity enhancer, they tend to use low dosages and oral route of administration. Infrequent use in these dosages is probably the best thing one can do to counteract the harm to the heart. Coincidentally, this is one reason why you don't see cases of pulmonary hypertension showing up (this is assuming it acts as a 5HT2B releaser/agonist). I'm sure if people abused it frequently, it would.
Let me reiterate, 5-HT2B releasing agents/agonists are to be feared when used chronically or/and in high dosages. A low dose, taken on an infrequent basis will likely not cause severe or lasting damage. (For instance, how often do you see pulmonary hypertension from MDMA use).
As mentioned by /u/Danyboyr we don't really know what exactly the fluorine moiety nor the metabolites of it will do. Take some of the chloro amphetamines for instance; they have terrible side effects and in some cases extreme potential for neurotoxicity (p-chloroamphetamine comes to mind). In general halogenated amphetamines are to be treated with caution until more research arises.
/u/MisterYouAreSoDumb, you mentioned in the past that you were researching 5-HT2B antagonists, do you know of any that are readily available?
u/MisterYouAreSoDumb
Nothing potent enough to displace things like 6-APB, but do not pass the BBB. Most pharma companies are targeting central 5-HT2B receptors. That means there is not a lot of information on peripheral selective 5-HT2B antagonists.